Find a Registered Dental Hygienist

GO

Knowledge Network

FACT SHEET: Bullous Pemphigoid (BP) has several clinical forms. These include “generalized”, “vesicular”, “urticarial”, “vegetative”, “generalized erythroderma”, “nodular”(pemphigoid nodularis), “acral”, “infant”, and “pregnancy” (pemphigoid gestationis1).

Date of Publication: June 20, 2017
GO TO:

Is the initiation of non-invasive dental hygiene procedures* contra-indicated?

  • No (assuming patient/client is already under medical care for BP).

Is medical consult advised? 

  • Yes, if suspect oral lesions have not yet been diagnosed. Biopsy is necessary for a definitive diagnosis.
  • Yes, if not already done, all patients/clients diagnosed with oral pemphigoid lesions should be referred to a dermatologist, as well as an ophthalmologist for assessment of ocular lesions. Examination by a gastroenterologist is advised for patients/clients with dysphagia or severe oral lesions to detect possible involvement of the esophagus.
  • Yes, if after treatment and remission, new lesions are observed. The dental hygienist should ensure referral back to the specialist physician for re-evaluation and further treatment.

Is the initiation of invasive dental hygiene procedures contra-indicated?**

  • Possibly, depending on disease control and treatment regimen.

Is medical consult advised? 

  • See above. 

Is medical clearance required? 

  • Possibly (e.g., if the disease is unstable and/or oral involvement is severe). Also, medical clearance may be required if patient/client is being treated with medications associated with immunosuppression +/- increased risk of infection (e.g., systemic corticosteroids2 [i.e., intravenous formulations or oral prednisone], methotrexate, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, and biologics [e.g., rituximab and etanercept]). Thrombocytopenia (low platelet count) is a side effect of many non-steroidal immunosuppressive drugs, and medical clearance may be required to rule out significant bleeding risk.

Is antibiotic prophylaxis required? 

  • No, not typically (although extended use of corticosteroids or cytotoxic drugs — particularly in the presence of leukopenia [low white blood cell count] — may warrant consideration of antibiotic prophylaxis).3 

Is postponing treatment advised?

  • Possibly (depends on severity and level of control of the disease, as well as medical clearance for patients/clients on medications associated with immunosuppression and/or thrombocytopenia).

Oral management implications

  • Oral prophylaxis should ideally be performed prior to the initiation of systemic or topical therapy.
  • Routine oral hygiene may be compromised due to pain in the mouth. During active oral disease, patient/client follow-up is recommended as frequently as every 4 to 6 weeks for debridement, and it should include monitoring for oral candidiasis. Gentle technique is important given the friability of oral tissues. During clinical remission, patient/client maintenance appointments should occur every 3 to 6 months, with as little disruption to oral tissue as possible.
  • Simple hand scaling instruments are often most effective, particularly if there is severe mucosal disease. If there is oral involvement, air polishers and abrasive products should be avoided due to the fragility of oral tissue. Gentle technique is important.
  • The dental hygienist should anticipate that the patient/client may experience pain and bleeding during procedures, and plan for this by scheduling extra time and using suction and gauze as needed.  
  • Occlusive topical steroid therapy may be indicated in some patients/clients. This can be accomplished by using custom-made trays to localize steroid application.
  • For discrete ulcers, intralesional therapy with an injectable corticosteroid (e.g. dexamethasone) may be beneficial. A dentist would typically administer this in conjunction with the patient/client’s physician.
  • Intraoral photography during appointments can assist in evaluating oral tissue involvement.
  • Patients/clients with oral manifestations should be advised to eat a balanced diet and to avoid rough, acidic, and spicy foods. Alcohol (including in mouth rinses) is contraindicated. During flare-ups, a soft and bland diet is preferred in order to minimize trauma to injured tissue, although this can lead to more plaque accumulation. During periods of remission, patients/clients generally have no dietary restrictions.
  • The dental hygienist plays a role in monitoring the patient/client for long-term effects of corticosteroid and immunosuppressive treatment.

Oral manifestations

  • Oral lesions are much less frequent than in mucous membrane pemphigoid (MMP), occurring in only a minority of patients/clients, and usually only when cutaneous disease is extensive. However, in childhood bullous pemphigoid, the mucous membranes are much more commonly involved than in adults with BP.
  • When they occur, the oral lesions are very similar to those of MMP. Bullae and erosions appear, particularly on the attached gingiva. Other areas of the gingiva may also be affected, as well as the buccal mucosa, soft palate, floor of the mouth, and tongue. Non-gingival mucosal lesions tend to be more extensive and painful.
  • Candidiasis may occur with the use of oral topical corticosteroids, as well as with systemic therapy.
  • Some drugs used to treat pemphigoid, such as cyclosporine, have side effects that include bleeding, oral ulcerations, stomatitis, and tender or swollen gums. Methotrexate can cause mouth sores, in addition to a sore throat.
  • Biologic response modifier drugs, such as tumour necrosis factor inhibitors (e.g., etanercept), can cause sore throat and nasal congestion.

Related signs and symptoms

  • Bullous pemphigoid is a subepidermal blistering disease. This chronic autoimmune condition manifests predominately as cutaneous lesions. Two-thirds of patients/clients only have skin lesions, with one-third having concomitant lesions of the mucous membranes (including mouth, tongue, pharynx, esophagus, and/or eyes). 
  • While relatively rare, BP is the most common autoimmune mucocutaneous blistering disease, with an estimated prevalence of 1 in 40,000. Incidence is estimated to be 7 to 10 new cases per million persons per year. BP tends to affect older persons more than mucous membrane pemphigoid (MMP), with no pronounced gender predilection. Peak incidence is in the seventh and eighth decades. There is no definitive cure.
  • Triggering factors can be identified in up to 15% of patients/clients. These include trauma (such as surgical procedures, burns, ultraviolet radiation, and ionizing radiation), infections, and certain medications (such as pembrolizumab and nivolumab [PD1-inhibitor immunotherapies, types of “checkpoint inhibitors”], furosemide [diuretic], carbamazepine [anticonvulsant], captopril [antihypertensive], penicillamine [chelating agent and disease-modifying antirheumatic drug], gliptins4 [antidiabetics], second-generation antipsychotics [olanzapine and risperidone], and antibiotics [amoxicillin, penicillin, and ciprofloxacin]). There may be an association with internal malignancy in some patients/clients.
  • Similar to MMP, BP lesions result from cleavage of the epithelium from underlying connective tissue at the basement membrane, without the acantholysis5 found in pemphigus vulgaris. Tense blisters are more characteristic of pemphigoid than of pemphigus. The fluid inside the blisters may be clear or contain blood. Unlike MMP, the blisters of BP usually heal without scarring.
  • Skin lesions typically occur on the trunk and limbs (although the whole body may be affected), sometimes starting with a very itchy, red, urticarial rash (hives). This non-bullous, prodromal rash may recur for several months, eventually evolving into areas that form vesicles and bullae that then break and leave sore, open skin. (See below.)
  • Bullous pemphigoid has several distinct clinical presentations6:
    • generalized bullous form, which is the most common; tense bullae arise on any part of the skin surface, with a tendency to occur in the flexural areas of the skin
    • vesicular form, which manifests as groups of small, tense blisters, often on an urticarial or erythematous (abnormally red) base
    • urticarial form, in which persistent urticarial lesions subsequently convert to bullous eruptions; in some patients/clients, urticarial lesions are the sole manifestations of the disease
    • vegetative form, which is very uncommon; vegetative plaques7 occur in skin folds, such as those of the axillae, groin, neck, and breasts
    • generalized erythroderma form, which is rare; it can resemble psoriasis, generalized atopic dermatitis, or other conditions with widespread redness and scaling of the skin
    • nodular form, which is rare; itchy nodules or plaques occur on arms, legs, and trunk, with or without blisters
    • acral form, in which the bullous lesions predominantly affect the palms and soles, and sometimes the face (particularly in childhood-onset BP)
    • infant form, in which infants younger than 1 year of age have blisters that occur most frequently on the palms, soles, and face, and rarely on the genital areas; 60% of these infant patients/clients also have generalized blisters
    • pregnancy form, which is rare; in pregnant or early post-partum patients/clients, extremely itchy skin papules and tense blisters develop; mucosal involvement occurs in less than 20% of affected persons.
  • While mortality does occur, this chronic disease is usually not life threatening. It can be a serious condition, especially in the elderly, persons in poor health, and persons not receiving treatment. Infection of blisters can lead to sepsis. Periods of disease exacerbation may be interspersed with periods of remission. BP can be self-limited, resolving after many months to years, even without therapy.
  • Osteoporosis, glaucoma, cataracts, type 2 diabetes mellitus, and infections are complications associated with long-term systemic corticosteroid therapy (e.g., prednisone).

References and sources of more detailed information


Date: February 16, 2017
Revised: April 1, 2022; June 22, 2025


FOOTNOTES

1 Pemphigoid gestationis was formerly named herpes gestationis despite no connection with herpes virus infection. 
2 Compared with pemphigus, BP usually responds to lower doses of systemic corticosteroids.
3 While not intended as antibiotic prophylaxis for oral procedures, some patients/clients are prescribed antibiotics (with particular anti-inflammatory properties) as part of their pemphigoid treatment regimen, including dapsone (which is also classified as an immunomodulatory agent), tetracycline, and erythromycin.
4 Gliptins are more formally referred to as dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors). They include alogliptin, sitagliptin, saxagliptin, linagliptin and vildagliptin. Median time to onset of bullous pemphigoid is 11 months after initiation of therapy. Mucosal involvement is more frequent than in “conventional” BP.
5 Acantholysis is breakdown of cellular adhesion between epithelial cells, which results in intraepithelial vesicle formation.
6 Diagnostic tests for bullous pemphigoid include skin/lesion biopsy and bloodwork for autoantibodies.
7 Vegetative plaques are raised, circumscribed, solid, and fleshy skin lesions. They may be wart-like or nipple-like, or they may have granulation tissue on the surface of the plaque.


* Includes oral hygiene instruction, fitting a mouth guard, taking an impression, etc.
** Ontario Regulation 501/07 made under the Dental Hygiene Act, 1991. Invasive dental hygiene procedures are scaling teeth and root planing, including curetting surrounding tissue.